NARCX | VFSAX | NARCX / VFSAX | |
Total Expense Ratio | N/A | N/A | - |
Annual Report Gross Expense Ratio | N/A | N/A | - |
Fund Existence | 30 years | 6 years | - |
Gain YTD | 2.690 | 0.709 | 379% |
Front Load | N/A | N/A | - |
Min. Initial Investment | 1000 | 3000 | 33% |
Min. Initial Investment IRA | N/A | N/A | - |
Net Assets | 291M | 10.4B | 3% |
Annual Yield % from dividends | 1.16 | 3.01 | 39% |
Returns for 1 year | 9.87 | 5.12 | 193% |
Returns for 3 years | 4.37 | -6.26 | -70% |
Returns for 5 years | 14.82 | 9.08 | 163% |
Returns for 10 years | 39.96 | N/A | - |
1 Day | |||
---|---|---|---|
MFs / NAME | Price $ | Chg $ | Chg % |
EAFGX | 28.16 | 0.49 | +1.77% |
Eaton Vance Focused Growth Opps A | |||
EEMHX | 8.02 | 0.02 | +0.25% |
MFS Emerging Markets Equity Research R6 | |||
JFNCX | 58.22 | 0.01 | +0.02% |
Janus Henderson Global Life Sciences C | |||
VWYGX | 44.71 | N/A | N/A |
Voya Small Cap Growth C | |||
WOOPX | 19.12 | -0.10 | -0.52% |
JPMorgan SMID Cap Equity I |